CHENGDU, China, July 16, 2024 /PRNewswire/ -- 'Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery' webinar will be jointly hosted by HitGen Inc. and Xtalks on Wednesday July 17, 2024, at 2pm EDT (11am PDT). Alex Shaginian, PhD, Vice President of Business Development and Chemical Sciences, HitGen, David Israel, PhD, Vice President of Lead Discovery Sciences, HitGen; and Rusty Montgomery, PhD, SVP-Research, BioAge Labs, will join the live webinar, and share their insights into the challenges in drug discovery and different selection strategies for DNA-encoded library (DEL) technology in the drug discovery process.

中国成都，2024年7月16日/PRNewswire/--“进化的DNA编码文库技术及其在创新药物发现中的应用”网络研讨会将于2024年7月17日星期三，美国东部夏令时下午2点（太平洋夏令时上午11点）由HitGen Inc.和Xtalks联合主办。Alex Shaginian博士，HitGen商业发展和化学科学副总裁，David Israel博士，HitGen铅发现科学副总裁；BioAge实验室高级副总裁Rusty Montgomery博士将参加现场网络研讨会，分享他们对药物发现面临的挑战以及药物发现过程中DNA编码文库（DEL）技术的不同选择策略的见解。

A detailed case study from BioAge on the discovery of novel inhibitors using DEL technology will be introduced..

将介绍BioAge关于使用DEL技术发现新型抑制剂的详细案例研究。。

DEL technology has seen remarkable advancements in recent years and has made a significant impact in successfully identifying a variety of hit compounds that have progressed to various stages of drug development. Proteins are the major targets used in DEL selection as they can be either extracted from biological samples or, more often, expressed in the recombinant form, which allows for different designs of protein constructs.

近年来，DEL技术取得了显着进步，并在成功鉴定已发展到药物开发各个阶段的各种命中化合物方面产生了重大影响。蛋白质是DEL选择中使用的主要靶标，因为它们可以从生物样品中提取，也可以更常见地以重组形式表达，这允许蛋白质构建体的不同设计。

DEL technology presents a disruptive hit identification platform that can vastly expedite the course of early-stage small-molecule drug discovery..

DEL技术提供了一个破坏性的命中识别平台，可以大大加快早期小分子药物发现的进程。。

In this free webinar, the expert speakers will provide an introduction to free selection on different target types ranging from enzymes to receptors and highlight the unique advantages or features for the application of DELs on these targets. They will also describe various DEL platforms that have been developed and how they can be utilized to achieve success in the drug discovery process..

在这个免费的网络研讨会上，专家发言人将介绍从酶到受体的不同目标类型的自由选择，并强调在这些目标上应用DEL的独特优势或功能。他们还将描述已经开发的各种DEL平台，以及如何利用它们在药物发现过程中取得成功。。

Furthermore, as a case study, BioAge Labs will share their experience in using DEL technology for their study entitled 'The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening', which was published in Bioorganic & Medicinal Chemistry Letters. In this work, the researchers have demonstrated a selection strategy for drug discovery using DEL, directly identified small molecule structures, biophysical and biochemical activities, physicochemical properties and other factors..

此外，作为一个案例研究，BioAge实验室将分享他们使用DEL技术进行研究的经验，该研究题为“通过DNA编码文库筛选发现新型有效的吲唑NLRP3抑制剂”，该研究发表在《生物有机与药物化学快报》上。在这项工作中，研究人员展示了使用DEL进行药物发现的选择策略，直接确定了小分子结构，生物物理和生化活性，理化性质和其他因素。。

Register for this webinar to understand how DEL technology can revolutionize small-molecule drug discovery.

注册本次网络研讨会，了解DEL技术如何彻底改变小分子药物的发现。

For more information, or to register for this event, visit Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery.

欲了解更多信息或注册此活动，请访问不断发展的DNA编码文库技术及其在创新药物发现中的应用。

About HitGen

关于HitGen

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD).

HitGen Inc.（SSE:688222。SH）是一家药物发现研究公司，总部位于中国成都，子公司位于英国剑桥和美国休斯顿。HitGen建立了领先的技术平台，可以发现和优化小分子和核酸药物。我们的关键技术平台包括世界领先的DNA编码文库技术（DEL），基于片段的药物发现和基于结构的药物设计技术（FBDD/SBDD），以及合成治疗性寡核苷酸技术（STO）和靶向蛋白质降解技术（TPD）的新兴技术平台。

Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage..

通过我们多样化和灵活的商业模式，我们与全球数百家生物制药研究组织建立了合作伙伴关系。HitGen拥有从早期发现到临床试验阶段的多项计划。。

CONTACTBrian Moloney | Chief Business Officer | +1-760-644-8468 | brian.moloney@hitgen.com.Alex Shaginian | VP Business Development & Chemical Sciences | +1-608-213-5682 | alex.shaginian@hitgen.com.Email: bd@hitgen.comOr visit www.hitgen.com

联系Brian Moloney |首席商务官|+1-760-644-8468 |brian.moloney@hitgen.com.AlexShaginian |商业发展与化学科学副总裁|+1-608-213-5682 |alex.shaginian@hitgen.com.Email时间：bd@hitgen.comOr访问www.hitgen.com

SOURCE HitGen Inc.

SOURCE HitGen公司。